Rodman David Malcom sold $206K of MLYS
Rodman David Malcom (Chief Medical Officer) sold 8,519 shares of Mineralys Therapeutics, Inc. (MLYS) at an average of $24.20 ($23.93–$25.00, $0.21M total) across 2 trades over 2026-06-10 to 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing confirms the CMO’s open-market sale size, timing, and that it was executed under a pre-arranged Rule 10b5-1 plan, which generally lowers interpretive risk.
Market read
Confirms a ~ $206k CMO open-market sale in MLYS executed under a 10b5-1 plan; useful for monitoring insider behavior but not a standalone fundamental catalyst.
What to watch
For traders, the key is whether there are concurrent non-10b5-1 insider sales, upcoming clinical/regulatory catalysts, or dilution/financing news—none are included in this filing excerpt.
Background
This is an SEC Form 4 insider transaction disclosure for Mineralys Therapeutics, Inc. (MLYS).
Ticker impact
Form 4 shows CMO Rodman David Malcom sold 8,519 shares of Mineralys Therapeutics in open-market trades ($206k total) under a 10b5-1 plan.
Likely limited immediate price impact; any effect is more sentiment/flow-related than fundamental.
The disclosure is primary (SEC Form 4) and company-specific, but the trades are explicitly covered by a pre-arranged 10b5-1 plan, reducing interpretive weight versus non-10b5-1 sales.
Market effects
Adds a datapoint on insider activity in small-cap biotech, but no sector-wide catalyst is provided.
None indicated.
None indicated.
Counterpoint
Because the sales are under a 10b5-1 plan, the trades may reflect liquidity/compensation mechanics rather than bearish expectations; price reaction may be muted.
Key entities
- issuerMineralys Therapeutics, Inc.
Company whose shares were sold by an insider (Form 4).
- insiderRodman David Malcom
Chief Medical Officer who sold 8,519 shares across two trades.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan noted as Yes, implying sales were scheduled in advance.
